TWST241220C47500
- 2.80
- +0.25+9.80%
Twist Bioscience Newsroom
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Twist Bioscience Named a Best Idea for 2025 at TD Cowen
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $58
Express News | Twist Bioscience Shares Are Trading Higher After Leerink Partners Maintained Its Hold Rating on the Stock
Cautious Outlook for Twist Bioscience Amid Regulatory Changes and Competitive Pressures
Express News | Scorpion Capital- Remain Short on Twist Bioscience
AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care
Twist Bioscience Full Year 2024 Earnings: EPS Misses Expectations
Twist Bioscience Price Target Lowered to $52 From $55 at Barclays
Twist Bioscience Corporation (TWST): Among the Best Genomics Stocks to Buy Right Now
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $52
Twist Bioscience Price Target Raised to $54.00/Share From $50.00 by Scotiabank
Scotiabank Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $54
A Quick Look at Today's Ratings for Twist Bioscience(TWST.US), With a Forecast Between $35 to $58
Express News | Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Analyst Ratings
Twist Bioscience Reports Record Revenue in 2024
Cautious Outlook: Unfavorable Risk/Reward Profile for Twist Bioscience Amid Market Concerns
Twist Bioscience | 10-K: FY2024 Annual Report
12 Health Care Stocks Moving In Monday's Pre-Market Session